Caressa Y Hui1, Soumon Rudra2, Sirui Ma2, Jian L Campian3, Jiayi Huang4. 1. Saint Louis University School of Medicine, Saint Louis, MO, 63104, USA. 2. Department of Radiation Oncology, Washington University School of Medicine, 4921 Parkview Place, Campus Box 8224, St. Louis, MO, 63110, USA. 3. Division of Oncology, Washington University School of Medicine, St. Louis, MO, 63110, USA. 4. Department of Radiation Oncology, Washington University School of Medicine, 4921 Parkview Place, Campus Box 8224, St. Louis, MO, 63110, USA. jiayi.huang@wustl.edu.
Abstract
PURPOSE: Corticosteroids are commonly used to alleviate symptoms from cerebral vasogenic edema in glioblastoma (GBM) patients. This study evaluated the impact of overall corticosteroid exposure during chemoradiotherapy (CRT) on acute severe lymphopenia (ASL) and survival outcomes of GBM patients. METHODS: GBM patients treated with CRT from 2007 to 2016 were retrospectively analyzed. Overall corticosteroid exposure was estimated as the average daily dexamethasone dose during 6 weeks of CRT. ASL was defined as grade 3 or higher lymphopenia within 3 months of starting CRT. ASL rates, overall survival (OS), and progression-free survival (PFS) were analyzed using Kaplan-Meier method. Multivariable analysis (MVA) was performed using logistic and Cox regression to identify independent predictors of ASL and survival outcomes, respectively. RESULTS: Of the 319 eligible patients, the median daily dexamethasone use was 2 mg/day. The high-dose dexamethasone cohort (> 2 mg/day) had significantly higher ASL and worse OS than the low-dose dexamethasone cohort: 3-month ASL of 43.7% versus 19.8% (p < 0.003) and median OS of 12.6 months versus 17.9 months (p < 0.001), respectively. On MVA, higher dexamethasone use was independently associated with higher ASL and worse OS, but not worse PFS. A subset analysis of patients with gross-total resection found that higher dexamethasone use was significantly associated with ASL, but not OS. CONCLUSION: Increased corticosteroid use among GBM patients during CRT appears to be an independent risk factor for developing subsequent ASL. Its apparent association with worse OS may be influenced by other confounding factors and would need to be validated through prospective investigations.
PURPOSE: Corticosteroids are commonly used to alleviate symptoms from cerebral vasogenic edema in glioblastoma (GBM) patients. This study evaluated the impact of overall corticosteroid exposure during chemoradiotherapy (CRT) on acute severe lymphopenia (ASL) and survival outcomes of GBM patients. METHODS: GBM patients treated with CRT from 2007 to 2016 were retrospectively analyzed. Overall corticosteroid exposure was estimated as the average daily dexamethasone dose during 6 weeks of CRT. ASL was defined as grade 3 or higher lymphopenia within 3 months of starting CRT. ASL rates, overall survival (OS), and progression-free survival (PFS) were analyzed using Kaplan-Meier method. Multivariable analysis (MVA) was performed using logistic and Cox regression to identify independent predictors of ASL and survival outcomes, respectively. RESULTS: Of the 319 eligible patients, the median daily dexamethasone use was 2 mg/day. The high-dose dexamethasone cohort (> 2 mg/day) had significantly higher ASL and worse OS than the low-dose dexamethasone cohort: 3-month ASL of 43.7% versus 19.8% (p < 0.003) and median OS of 12.6 months versus 17.9 months (p < 0.001), respectively. On MVA, higher dexamethasone use was independently associated with higher ASL and worse OS, but not worse PFS. A subset analysis of patients with gross-total resection found that higher dexamethasone use was significantly associated with ASL, but not OS. CONCLUSION: Increased corticosteroid use among GBM patients during CRT appears to be an independent risk factor for developing subsequent ASL. Its apparent association with worse OS may be influenced by other confounding factors and would need to be validated through prospective investigations.
Authors: Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi Journal: Clin Cancer Res Date: 2011-07-07 Impact factor: 12.531
Authors: Jiayi Huang; Todd A DeWees; Shahed N Badiyan; Christina K Speirs; Daniel F Mullen; Sandra Fergus; David D Tran; Gerry Linette; Jian L Campian; Michael R Chicoine; Albert H Kim; Gavin Dunn; Joseph R Simpson; Clifford G Robinson Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-08 Impact factor: 7.038
Authors: Michael A Hughes; Michele Parisi; Stuart Grossman; Lawrence Kleinberg Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-01 Impact factor: 7.038
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Akshitkumar M Mistry; Sumeeth V Jonathan; Meredith A Monsour; Bret C Mobley; Stephen W Clark; Paul L Moots Journal: Neurooncol Pract Date: 2021-06-23
Authors: Paula Aldaz; Jaione Auzmendi-Iriarte; Maika Durántez; Irene Lasheras-Otero; Estefania Carrasco-Garcia; M Victoria Zelaya; Laura Bragado; Ana Olías-Arjona; Larraitz Egaña; Nicolás Samprón; Idoia Morilla; Marta Redondo-Muñoz; Mikel Rico; Massimo Squatrito; Marta Maria-Alonso; Joaquín Fernández-Irigoyen; Enrique Santamaria; Iñaki M Larráyoz; Claudia Wellbrock; Ander Matheu; Imanol Arozarena Journal: Cancers (Basel) Date: 2021-01-19 Impact factor: 6.639
Authors: Katja Werlenius; Giuseppe Stragliotto; Michael Strandeus; Malin Blomstrand; Helena Carén; Asgeir S Jakola; Bertil Rydenhag; Dorte Dyregaard; Karine N Dzhandzhugazyan; Alexei F Kirkin; Martin K Raida; Anja Smits; Sara Kinhult Journal: Neurooncol Adv Date: 2021-10-22
Authors: J K Wiencke; Annette M Molinaro; Gayathri Warrier; Terri Rice; Jennifer Clarke; Jennie W Taylor; Margaret Wrensch; Helen Hansen; Lucie McCoy; Emily Tang; Stan J Tamaki; Courtney M Tamaki; Emily Nissen; Paige Bracci; Lucas A Salas; Devin C Koestler; Brock C Christensen; Ze Zhang; Karl T Kelsey Journal: Nat Commun Date: 2022-09-20 Impact factor: 17.694
Authors: Martin Voss; AbdulAziz Batarfi; Eike Steidl; Marlies Wagner; Marie-Thérèse Forster; Joachim P Steinbach; Claus M Rödel; Jörg Bojunga; Michael W Ronellenfitsch Journal: J Clin Med Date: 2019-10-03 Impact factor: 4.241